#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Myelofibrosis Hypoparathyroidism Immune-mediated enterocolitis Mucopolysaccharidosis III Cluster headache Ventricular tachycardia Cutaneous T-cell lymphoma Acute hepatic failure Kaposi's sarcoma Acquired haemophilia Breast cancer metastatic Cutaneous T-cell lymphoma stage I Autologous haematopoietic stem cell transplant Pseudoxanthoma elasticum Hyperadrenocorticism More trials…

    Learn about Rare Diseases

    Tuberous sclerosis complex Hereditary neuropathic amyloidosis – Life with Disease Mitochondrial myopathy – Diagnostics Mast cell activation syndrome – Trials in Disease Fragile X syndrome – Trials in Disease Extranodal marginal zone B-cell lymphoma (MALT type) – Life with Disease Choroid melanoma – Treatment Tuberous sclerosis complex – Life with Disease Pituitary-dependent Cushing’s syndrome Cystic fibrosis lung – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Indacaterol Maleate Syn321 Hyoscine Meropenem Tramadol Hydrochloride HYALURONIDASE Amoxicillin STREPTOCOCCUS PYOGENES Aon-D21 Emtricitabine Clemizole Hydrochloride Vixarelimab Forimtamig Cefiderocol Ketamine Hydrochloride Aminohippuric Acid Davutamig Cd7-Cart01 OMTX705 Brexpiprazole More therapies…

    Learn about Your Condition

    Lupus nephritis Ewing's sarcoma recurrent Pancreatic fistula Head and neck cancer Lichen sclerosus Toxic nodular goitre Ovarian granulosa cell tumour Pseudomyxoma peritonei Cushing's syndrome Diabetic neuropathy Malabsorption Malignant mast cell neoplasm Fatty acid oxidation disorder Cholangitis sclerosing Red blood cell abnormality More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Metastatic neoplasm

  • A Study of IPN01203 for Adults With Advanced or Metastatic Solid Tumors After Immune Checkpoint Inhibitor Treatment

    Recruiting

    2 1 1
    France Spain

  • Evaluation of drug combination therapy (olaparib, nilotinib, tremelimumab, and durvalumab) for patients with advanced or metastatic solid tumors

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Metastatic neoplasm
    Investigated Drugs:
    • Nilotinib
    • Durvalumab
    • Olaparib
    France

  • Study on Adding Zoledronic Acid or Denosumab to Radiotherapy for Adults with Inoperable Vertebral Bone Metastases

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Cancer pain
    • Metastatic neoplasm
    Investigated Drugs:
    • Denosumab
    • Zoledronic Acid Monohydrate
    France

  • Study on Treating Advanced Cancers with BRAF Mutations Using Sorafenib and Trametinib for Patients with Impaired Kinase Activity

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • BRAF gene mutation
    • Metastatic neoplasm
    Investigated Drugs:
    • Trametinib
    • Sorafenib
    Germany

  • Study of TAK-280, Tocilizumab, and Siltuximab for Patients with Advanced or Metastatic Cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Tak-280
    • Siltuximab
    • Tocilizumab
    France Spain

  • Study on the Effects of Trastuzumab Deruxtecan in Patients with Advanced or Metastatic Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Metastatic neoplasm
    Investigated Drugs:
    • Trastuzumab Deruxtecan
    Spain
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!